We discovered that Esc peptides are highly efficient in reducing the level of infection in a mouse model of keratitis upon local administration in a drop-wise fashion. Our current aim is the development of our peptides as new ophthalmic agents for treatment of bacterial keratitis, as well as to produce antimicrobial contact lenses for preventative usage to avoid eye infection. US PATENT “Esculentin 1a Derivatives and Uses Thereof”
